the biomedicine integrated r & d service base of beijing leadingpharm has landed in yongchuan, chongqing-澳门凯发

on august 23, the smart china expo 2021 key projects of investment promotion and signing activities of major projects signing ceremony was held in chongqing yuelai international convention center. a total of 92 projects were signed in chongqing with a contract amount of 252.4 billion yuan (excluding the centralized signing projects held separately by various districts and counties in chongqing). as one of the key projects in chongqing, the project of leadingpharm (chongqing) cxo biomedical integrated r & d service base was intensively signed at the meeting.
 

leadingpharm will continue to invest in yongchuan district of chongqing to build a cxo biomedical integrated r & d service base, integrating leadingpharm (chongqing) research institute, mah company, cro company of cell gene therapy, cdmo base, chongqing mah information platform and management center, so as to promote the construction of sichuan-chongqing biomedical industry cluster and build a big health industry highland in the west.
 

yongchuan district of chongqing

as one of the five old pharmaceutical industrial bases in china, chongqing has strong production capacity and technological accumulation of chemical medicine equipment, obvious characteristics of traditional chinese medicine, outstanding advantages of independent innovation of medical devices, and rich clinical resources in sichuan and chongqing. according to the deployment of chongqing action plan for promoting the high-quality development of big health industry (2020-2025), by 2025, "a number of big health industry clusters with strong driving effect will be formed, which will become an important pillar industry of the city and basically build a national leading area for the integrated development of big health industry".

beijing leadingpharm

beijing leadingpharm was established in 2005. it is the first pharmaceutical r & d enterprise listed on the main board in china. it has won the honorary titles of national high-tech enterprise, top 10 pharmaceutical r & d companies in china, star vice president unit of medical and pharmaceutical chamber of commerce of all-china federation of industry and commerce, etc. based on the international perspective, after 17 years of accumulation, leadingpharm has gradually formed the core competitive advantage of "internationalization, integration and industrialization", and has a perfect drug r & d management system, rich project experience and senior expert teams at home and abroad. it has formed a cxo service system covering the whole industrial chain covering preclinical research, cro and cdmo. in addition, leadingpharm has established good strategic cooperative relations with more than 500 enterprises, r & d institutions, universities and capital institutions at home and abroad, covering the whole country, europe, america, japan and south korea.
 

▲ tao xinhua, chairman of leadingpharm delivered a speech at the yongchuan special signing ceremony of smart china expo online
 

by this cooperation, leadingpharm will make full use of its advantages in technology, management and resources, combined with chongqing yongchuan district's rich clinical resources, strong talent reserve, excellent business environment and policy support, and strive to promote the high-quality development of biomedical industry in sichuan and chongqing through multi-level in-depth cooperation, mutual benefit and win-win results.

in addition, the conclusion of this cooperation also marks the further expansion of leadingpharm’s cxo strategy, comprehensively entering the western region of china, and will comprehensively help the sichuan chongqing twin city economic circle to build a biomedical industry cluster with national influence and rise a new medical force in western.
 

-end-